Introduction Human society has made a tremendous leap in the technological space and advances in medical science in the recent decades. From the age where Shaman’s were in charge of life, to today’s world of genomic sequencing, the rate and impact of advancement has been astounding. We are now at the cusp of the next big paradigm shift with genetic testing becoming a more commonplace in the clinic, and the clinical research and clinical care are more closely connected than ever. Genomic sequencing technology provides a new world of promising array of tests for clinical practice, including the sequencing of entire genome, measuring one’s complete DNA sequence and all genes coding for proteins. These technologies make it possible to test for multiple genes in a single test, which increases the efficiency of genetic testing (ACOG, 2008). The cost of sequencing a human genome is now less than $5,000 and takes only a day or two. This means genome analysis is now increasingly affordable and potentially clinically meaningful, giving access to tests that can be used to detect and monitor a disease, assess risk factors or inform the selection of drugs (Cadwallad C, 2013). There are more than 14,000 genetic tests for over 4,000 diseases and conditions in the National Institute of Health’s Genetic Testing Registry (GTR; Rojahn, S. Y, 2013). Genomics is making its biggest stride in all areas of medicine, as attractive as it sounds it entails daunting challenges and raises multiple ethical questions (Burke, W., Trinidad, S. B., & Clayton, E. W., 2013). These ethical questions arise because of conflicts of current norms of religion, moral values and relate to accuracy, cost and confidentiality (Fulda, K., & Lykens, K 2006). Challenges - Range of Ethical Issues Serious ethical questions surround both genetic testing of individuals and genetic screening of populations. - Should genetic testing be a personal choice? - Who should be tested? What is the purpose of testing- diagnostic, predictive or carrier testing? - Who all have access to the genetic information and who owns the data? - What should you do with the information? - Rights around disclosure of the condition to the biologic family? - What does a particular genetic alteration mean personally, medically, and socially? - If we can, should we intervene to correct or enhance an individual's genome? - If not, how do we handle diagnostic information in the absence of a cure? - Are physicians aware of the current tests and their limitations? Are they trained to disclose the information to their patients and counsel as needed? Consider a case of a daughter, Meghan who wants to know the chances of her "future" children inheriting Huntington’s disease (HD). Her mother, Anne prefers that Meghan does not get genetically tested as it affects her life as well. She chooses to live without knowing if she carries the gene. Anne’s brother had the disease in his late life, suffered, and had an untimely death (McLean, M. R, 2013). Symptoms of HD, include uncontrolled movements, loss of mental abilities, and emotional disturbances, and are caused by the progressive death of neurons in certain areas of the brain. Death from related complications usually occurs 10 to 30 years following onset of symptoms. There is currently no treatment for this disease, nor is there anything an affected person can do to prevent the inevitable onset of symptoms (Norrgard, K. 2008). Huntington's is a dominant genetic disease, that gets passed down from parents to children. Children of parents afflicted with the disease have a 50 percent chance of having the disease. Until recently, there was no way of knowing if people carried the gene until symptoms actually appeared, usually between the ages of 30 and 50. In 1993, scientists identifie